Oncogene - Table of Contents alert Volume 36 Issue 23

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 36, Issue 23 (June 2017) In this issue Review Original Articles Letters to the Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Celebrating 30 years of Oncogene — 1987 to 2017 Thank you to the editors, board members, contributors, reviewers and readers, past and present for their invaluable contributions, and for bringing the journal to this milestone.  Watch our anniversary video showing a brief impact overview >>>   Review Top Rho GTPases: Anti- or pro-neoplastic targets? I Zandvakili, Y Lin, J C Morris and Y Zheng Oncogene 2017 36: 3213-3222; advance online publication, December 19, 2016; 10.1038/onc.2016.473 Abstract | Full Text Original Articles Top Analysis of DNA methylation in single circulating tumor cells C F Pixberg, K Raba, F Müller, B Behrens, E Honisch, D Niederacher, H Neubauer, T Fehm, W Goering, W A Schulz, P Flohr, G Boysen, M Lambros, J S De Bono, W T Knoefel, C Sproll, N H Stoecklein and R P L Neves Oncogene 2017 36: 3223-3231; advance online publication, January 9, 2017; 10.1038/onc.2016.480 Abstract | Full Text Upregulation of RET induces perineurial invasion of pancreatic adenocarcinoma M Amit, S Na'ara, L Leider-Trejo, Y Binenbaum, N Kulish, E Fridman, A Shabtai-Orbach, R J Wong and Z Gil Oncogene 2017 36: 3232-3239; advance online publication, January 16, 2017; 10.1038/onc.2016.483 Abstract | Full Text miR-19a promotes colitis-associated colorectal cancer by regulating tumor necrosis factor alpha-induced protein 3-NF-κB feedback loops T Wang, X Xu, Q Xu, J Ren, S Shen, C Fan and Y Hou Oncogene 2017 36: 3240-3251; advance online publication, December 19, 2016; 10.1038/onc.2016.468 Abstract | Full Text PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma J Delyon, A Servy, F Laugier, J André, N Ortonne, M Battistella, S Mourah, A Bensussan, C Lebbé and N Dumaz Oncogene 2017 36: 3252-3262; advance online publication, January 16, 2017; 10.1038/onc.2016.469 Abstract | Full Text Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia OPEN E J Pomeroy, L A Lee, R D W Lee, D K Schirm, N A Temiz, J Ma, T A Gruber, E Diaz-Flores, B S Moriarity, J R Downing, K M Shannon, D A Largaespada and C E Eckfeldt Oncogene 2017 36: 3263-3273; advance online publication, December 19, 2016; 10.1038/onc.2016.471 Abstract | Full Text Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma OPEN C Worrall, N Suleymanova, C Crudden, I Trocoli Drakensjö, E Candrea, D Nedelcu, S-I Takahashi, L Girnita and A Girnita Oncogene 2017 36: 3274-3286; advance online publication, January 16, 2017; 10.1038/onc.2016.472 Abstract | Full Text 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells S Ros, J Flöter, I Kaymak, C Da Costa, A Houddane, S Dubuis, B Griffiths, R Mitter, S Walz, S Blake, A Behrens, K M Brindle, N Zamboni, M H Rider and A Schulze Oncogene 2017 36: 3287-3299; advance online publication, January 16, 2017; 10.1038/onc.2016.477 Abstract | Full Text Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera T Tsuruta-Kishino, J Koya, K Kataoka, K Narukawa, Y Sumitomo, H Kobayashi, T Sato and M Kurokawa Oncogene 2017 36: 3300-3311; advance online publication, January 9, 2017; 10.1038/onc.2016.478 Abstract | Full Text FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation H Zhou, Y Liu, R Zhu, F Ding, Y Wan, Y Li and Z Liu Oncogene 2017 36: 3312-3321; advance online publication, January 9, 2017; 10.1038/onc.2016.479 Abstract | Full Text KLF4 is regulated by RAS/RAF/MEK/ERK signaling through E2F1 and promotes melanoma cell growth OPEN M Riverso, V Montagnani and B Stecca Oncogene 2017 36: 3322-3333; advance online publication, January 9, 2017; 10.1038/onc.2016.481 Abstract | Full Text Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition H S Kim, M Jung, H N Kang, H Kim, C-W Park, S-M Kim, S J Shin, S H Kim, S G Kim, E K Kim, M R Yun, Z Zheng, K Y Chung, J Greenbowe, S M Ali, T-M Kim and B C Cho Oncogene 2017 36: 3334-3345; advance online publication, January 16, 2017; 10.1038/onc.2016.486 Abstract | Full Text MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia OPEN K H M Prange, A Mandoli, T Kuznetsova, S-Y Wang, A M Sotoca, A E Marneth, B A van der Reijden, H G Stunnenberg and J H A Martens Oncogene 2017 36: 3346-3356; advance online publication, January 23, 2017; 10.1038/onc.2016.488 Abstract | Full Text Letters to the Editor Top CIP2A confirms its prognostic value in triple-negative breast cancer I Cristóbal, S Zazo, B Torrejón, M Pedregal, J Madoz-Gúrpide, A Lluch, P Eroles, A Rovira, J Albanell, J García-Foncillas and F Rojo Oncogene 2017 36: 3357-3358; advance online publication, January 9, 2017; 10.1038/onc.2016.474 Full Text Advertisement LOGO nature.com webcasts Join us for our upcoming webcast followed by live Q&A:  MAKING A NAME IN CANCER IMMUNOTHERAPY Presented by BioPharma Dealmakers Date: Tuesday, 13 June, 2017 Time: 8AM PDT | 11AM EDT | 4PM BST | 5PM CEST REGISTER FOR FREE Sponsored by: Immunomic Therapeutics, Inc., | IsoPlexis | Merus N.V. | Actinium Pharmaceuticals, Inc.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.